CD274 and head and neck squamous cell carcinoma: The TIGIT inhibitor tiragolumab is currently being used primarily in combination with anti-PD-L1 drugs in clinical trials in HNSCC, with two phase II studies (NCT03708224 and NCT04665843) underway.